Drug Trial Radar · NCT01830660
A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers
Last checked: Nov 20, 2026Latest source record: Apr 6, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
96
Planned (sponsor's estimate)
Start
Apr 2012
Primary completion
Jun 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 12, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Hetrombopag Olamine made by Jiangsu Hengrui Medicine co Ltd. has shown an effect of increasing platelet count in animal and human. This study is designed in dose escalation fashion to evaluate safety, pharmacokinetics and efficacy of Hetrombopag Olamine.
Conditions
- Healthy
Interventions
Hetrombopag Olamine TabletsDrug
placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in platelet count above baseline(%)on Day1,3,5,8,10,12,15,17,19,22,25,28 after dosingTime frame: up to 4 weeks
- Composite pharmacokinetic (PK) parameters of eltrombopag following a single dose of eltrombopagTime frame: For 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.